PYXS data shows 36% response and 94% disease control
PYXS reports MICVO results in heavily pretreated recurrent/metastatic head and neck cancer: 36% objective response rate, 94% disease control rate, and 6.2-month median progression-free survival. No new safety signals; dose capping improved tolerability.
MICVO showed a 36% objective response rate and 94% disease control rate in heavily pretreated recurrent/metastatic head and neck cancer, with a median progression-free survival of 6.2 months and no new safety signals. Dose capping improved tolerability, and a pivotal Phase 3 trial is planned for 20…